Modality
Nanobody
MOA
PRMT5i
Target
KRASG12C
Pathway
Neuroinflam
Heart FailureNSCLC
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
Jan 2017
→ Dec 2027
Phase 1Current
NCT04606202
2,529 pts·Heart Failure
2019-01→2027-12·Recruiting
NCT08900793
2,754 pts·Heart Failure
2017-01→2026-03·Completed
5,283 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-172w agoInterim· Heart Failure
2027-12-081.7y awayInterim· Heart Failure
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Complet…
P1
Recruit…
Catalysts
Interim
2026-03-17 · 2w ago
Heart Failure
Interim
2027-12-08 · 1.7y away
Heart Failure
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04606202 | Phase 1 | Heart Failure | Recruiting | 2529 | FEV1 |
| NCT08900793 | Phase 1 | Heart Failure | Completed | 2754 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP |